Search
-
‘Real world’ data shows 83 percent effectiveness for Bexsero® in infants in first year of UK national meningitis B immunisation programme
Media
Cases of meningitis B halved after ten months
https://www.gsk.com/en-gb/media/press-releases/real-world-data-shows-83-percent-effectiveness-for-bexsero-in-infants-in-first-year-of-uk-national-meningitis-b-immunisation-programme/
First published: 05 September 2016
-
FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over
Media
The data supports the efficacy and safety of Shingrix for the prevention of herpes zoster (shingles) in adults ages 50 and over.
https://www.gsk.com/en-gb/media/press-releases/fda-advisory-committee-votes-unanimously-for-shingrix-hzsu-in-the-us-for-prevention-of-herpes-zoster-shingles-in-adults-ages-50-and-over/
First published: 13 September 2017
-
GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
Media
GlaxoSmithKline plc announced that it has received Breakthrough Therapy Designation from the U.S. FDA for its meningitis B vaccine Bexsero
https://www.gsk.com/en-gb/media/press-releases/gsk-s-meningitis-b-vaccine-bexsero-receives-breakthrough-therapy-designation-from-us-fda-for-prevention-of-invasive-meningococcal-disease-in-children-2-10-years-of-age/
First published: 07 February 2018
-
GSK receives US approval of Arnuity Ellipta for use in children from 5 years old who suffer from asthma
Media
GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-approval-of-arnuity-ellipta-for-use-in-children-from-5-years-old-who-suffer-from-asthma/
First published: 21 May 2018
-
GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK
Media
GlaxoSmithKline plc and Adaptimmune Therapeutics plc, announced the transition of the development programme for GSK3377794 to GSK.
https://www.gsk.com/en-gb/media/press-releases/gsk-and-adaptimmune-complete-transition-of-ny-eso-spear-t-cell-therapy-programme-to-gsk/
First published: 24 July 2018
-
Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
Media
TESARO announced the presentation of data from the Phase 1/2 GARNET study
https://www.gsk.com/en-gb/media/press-releases/data-from-garnet-study-indicates-robust-activity-of-dostarlimab-in-patients-with-advanced-or-recurrent-endometrial-cancer/
First published: 19 March 2019
-
GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development
Media
GSK announced that it has licensed its M72/AS01E3 tuberculosis disease (TB) vaccine.
https://www.gsk.com/en-gb/media/press-releases/gsk-licenses-tuberculosis-vaccine-candidate-to-the-bill-melinda-gates-medical-research-institute-for-continued-development/
First published: 27 January 2020
-
Update - GSK Consumer Healthcare
Media
GlaxoSmithKline (GSK) plc today confirms it has received three unsolicited, conditional and non-binding proposals from Unilever plc
https://www.gsk.com/en-gb/media/press-releases/update-gsk-consumer-healthcare/
First published: 15 January 2022
-
China approves Cervarix two-dose vaccine schedule for girls aged 9 to 14 against certain types of cancer-causing human papillomavirus
Media
China’s National Medical Products Administration has approved a two-dose vaccine schedule for Cervarix in girls aged between 9 to 14 years.
https://www.gsk.com/en-gb/media/press-releases/china-approves-cervarix-two-dose-vaccine-schedule-for-girls-aged-9-to-14-against-certain-types-of-cancer-causing-human-papillomavirus/
First published: 27 May 2022
-
Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer
Media
Regulatory submissions based on the trial results are planned for the first half of 2023.
https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-ruby-phase-iii-trial-met-its-primary-endpoint-in-a-planned-interim-analysis-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer/
First published: 02 December 2022